Abstract
Golgi α-mannosidase II, a key enzyme in N-glycan processing, is a target in the development of anticancer therapies. The crystal structure of Drosophila Golgi α-mannosidase II in the absence and presence of the anti-cancer agent swainsonine and the inhibitor deoxymannojirimycin reveals a novel protein fold with an active site zinc intricately involved both in the substrate specificity of the enzyme and directly in the catalytic mechanism. Identification of a putative GlcNAc binding pocket in the vicinity of the active site cavity provides a model for the binding of the GlcNAcMan5GlcNAc2 substrate and the consecutive hydrolysis of the α1,6- and α1,3-linked mannose residues. The enzyme-inhibitor interactions observed provide insight into the catalytic mechanism, opening the door to the design of novel inhibitors of α-mannosidase II.
Original language | English |
---|---|
Pages (from-to) | 3008-3017 |
Number of pages | 10 |
Journal | EMBO Journal |
Volume | 20 |
Issue number | 12 |
DOIs | |
Publication status | Published - 15 Jun 2001 |
Keywords
- Cancer therapy
- Drug design
- Golgi α-mannosidase II
- N-glycosylation pathway
- X-ray crystallography
ASJC Scopus subject areas
- General Neuroscience
- Molecular Biology
- General Immunology and Microbiology
- General Biochemistry,Genetics and Molecular Biology